Portfolio News
Seoul & Gwangju, South Korea, 14 July, 2025 – MicroPort® CardioFlow recently announced the successful completion of the first commercial implantations of its VitaFlow Liberty® Transcatheter Aortic Valve Implantation (TAVI) system in South Korea. A total of five cases were performed across two leading cardiovascular centers: Seoul St. Mary’s Hospital (The Catholic University of Korea) and Chonnam National University Hospital.
The procedures were proctored by Professor Junjie Zhang, Vice President of Nanjing First Hospital, and performed by Dr. Chang Ki Yuk from Seoul St. Mary’s Hospital and Dr. Kim Juhan from Chonnam National University Hospital. Postoperative assessments confirmed successful outcomes with no significant paravalvular leakage or complications, including in a 90-year-old patient with severe aortic stenosis. Both the proctor and local physicians expressed strong confidence in the system’s performance.
“Under Professor Zhang’s guidance, VitaFlow Liberty® demonstrated excellent performance and stable deployment.” Said Dr. Chang Ki Yuk.
Dr. Kim Juhan added, “The system’s precision and stability gave us strong confidence in treating complex cases.”
VitaFlow Liberty® builds upon the proven design of its predecessor, VitaFlow®, incorporating a hybrid-density self-expanding stent, bovine pericardial leaflets, and an advanced double-layer PET skirt. These features provide strong radial support, improved coaxial deployment, and reduced perivalvular leakage post-procedure. Furthermore, its next-generation delivery system incorporates a unique and innovative double-reinforced spiral structure that ensures rapid, stable, and precise release and retrieval. This system also provides flexibility, allowing for 360-degree bending of the valve segment.
The successful launch of VitaFlow Liberty® in South Korea marks a significant milestone in MicroPort® CardioFlow’s global expansion. Looking ahead, the company remains committed to advancing innovative structural heart solutions and delivering high-quality care to patients worldwide.
